This was demonstrated in two patients with ACTH-secreting PC responding positively to pembrolizumab, while tumors without hypermutator phenotypes did not respond, raising questions about the role of immune markers and tumor genetics in CPI responsiveness. The gene discussed is POMC; the disease is pachyonychia congenita.